Anticoagulant effects of a synthetic peptide containing residues Thr-2253-Gln-2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalysed factor VIII activation

British Journal of Haematology

Volumn 116, Issue 4, 2002, Pages 868-874

  Nogami, Keiji ^a   Shima, Midori ^a   Nishiya, Katsumi ^a   Hosokawa, Kazuya ^b   Saenko, Evgueni L ^c   Giddings, John C ^d   Tanaka, Ichiro ^a   Yoshioka, Akira ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Fujimori Kogyo CO   (Japan)

^c HOLLAND LABORATORY   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anticoagulation; C2 domain; Factor VIII; Factor Xa; Synthetic peptide

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 DERIVATIVE; BLOOD CLOTTING FACTOR 9A; EPITOPE; GLUTAMINE; GLYCINE; PEPTIDE EP2; PHOSPHOLIPID; PROTEINASE; THREONINE; THROMBIN; UNCLASSIFIED DRUG; VALINE;

ANTICOAGULATION; ARTICLE; BINDING SITE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTHROMBIN TIME; THROMBOPLASTIN TIME; THROMBOSIS;

ANTICOAGULANTS; BLEEDING TIME; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR V; FACTOR VIII; FACTOR XA; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTEIN BINDING;

EID: 0036124720     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1048.2002.03360.x     Document Type: Article

References (32)

1. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
2. A simple method for the preparation of homogeneous phospholipid vesicles
3. The role of phospholipid and factor VIIIa in the activation of bovine factor X
4. Anticoagulant effects of the selective factor Xa inhibitors tick anticoagulant peptide and antistatin in the APTT assay are determined by the relative rate of prothrombinase inhibition
5. Antistatin, a leech-derived inhibitor of factor Xa kinetic analysis of enzyme inhibition and identification of the reactive site
6. Proteolytic processing of human FVIII. Correlation of specific cleavages by thrombin, FXa and activated protein C with activation and inactivation of FVIII coagulant activity
7. Synthetic factor. VIII peptides with amino sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidyl serine
8. Preparation of anhydrothrombin and characterization of its interaction with normal thrombin substrates
9. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acid
10. High levels of factor IX increase the risk of venous thrombosis
11. Blood coagulation factors V and VIII; structural and functional similarities and their relationships to hemorrhagic and thrombotic disorders
12. A new animal model of thrombophilia confirms that plasma factor VIII levels are thrombogenic
13. The effect of von Willebrand factor on activation of factor VIII by factor Xa
14. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
15. Localization of a factor X interactive site in the A1 subunit of factor VIIIa
16. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor. VIII
17. A comparison of phospho-lipid and platelets in the activation of human factor VIII by thrombin and factor Xa, and in the activation of factor X
18. Thrombin-activated and factor Xa-activated human factor VIII: C differences in cofactor activity and decay rate
19. Role of factor VIII. C2 domain in factor VIII binding to factor Xa
20. 1689
21. Discovery of a novel, potent, and specific family of factor Xa inhibitor via combinatorial chemistry
22. Subunit structure and function of porcine factor Xa-activated factor VIII
23. High levels of factor VIII and venous thrombosis
24. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition
25. Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor
26. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes
27. Structure of human factor VIII
28. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistatin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis
29. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa
30. Stabilization of factor VIII in plasma by the von Willebrand factor
31. Expression of active human factor VIII from recombinant DNA clones
32. Immunoassays of factor IX antigen using mono-clonal antibodies